Microdosing LSD for Health & Longevity

Evidence Review created on 09/29/2026 using AI4L + evidence-mcp / Opus 5.5

Also known as: LSD Microdosing, Microdosed LSD, Low-Dose LSD, Sub-Perceptual LSD, Lysergic Acid Diethylamide, Lysergide, LSD-25, Delysid, MB22001, MM120, DT120

Motivation

Microdosing LSD (lysergic acid diethylamide) means taking a very small amount of the psychedelic drug — roughly a tenth to a twentieth of a dose that causes hallucinations — every few days. The amount is chosen to stay below the level that changes perception. The drug acts on the brain chemistry that regulates mood and thinking, which is why people take it hoping for better mood and focus.

The practice spread from a small circle of psychedelic researchers to technology workers, athletes, and health-focused adults, many of whom treat it as a long-term habit. Because the drug is illegal in most countries, most people source it informally, and dosing is often imprecise. Interest has drawn a wave of placebo-controlled studies, drug-company programs, and academic debate about how much of the reported experience comes from the drug itself and how much from expectation.

This review examines what controlled studies, research on how the drug acts in the body, and practitioner experience show about repeated low-dose LSD: its effects on mood and thinking; its short- and long-term risks, including heart-valve concerns; and the practical, legal, and monitoring questions relevant to health-focused adults.

Benefits - Risks - Protocol - Conclusion

This section lists expert commentary, podcasts, and narrative reviews that give a high-level overview of LSD microdosing.

No directly relevant content was found from Peter Attia (site searches returned no microdosing or LSD content beyond a passing psilocybin mention), Lifespan.io (no microdosing articles), or Life Extension Magazine (no article located; the site search was blocked). Chris Kresser’s only relevant content, a Ben Greenfield interview, covers LSD microdosing in a brief anecdotal segment, not in depth. Rhonda Patrick’s only relevant content, a short FoundMyFitness digest of a single survey dominated by psilocybin users, does not discuss LSD microdosing in depth. Only three sources met the depth and eligibility criteria, so the list is not padded to five.

Grokipedia

  • Psychedelic microdosing

    Covers definitions, LSD and psilocybin dose ranges, history, pharmacology, claimed effects versus trial evidence, health risks, and skeptical perspectives in one structured article.

Examine

  • LSD

    Examine’s LSD page briefly summarizes the drug’s history and preliminary therapeutic research in psychiatric disorders and links a research feed of study summaries, most of which require a subscription.

ConsumerLab

No ConsumerLab article on LSD or LSD microdosing exists. ConsumerLab tests dietary supplements and does not typically cover controlled substances or prescription medications, so LSD falls outside its scope.

Systematic Reviews

These systematic reviews (structured surveys of all published studies) and meta-analyses (statistical pooling of study results) pool controlled and observational studies of LSD and psilocybin microdosing on mood, cognition, and side effects.

Mechanism of Action

LSD is a partial agonist (a molecule that switches a receptor on, but not fully) at the serotonin 2A receptor (5-HT2A, the main target through which classic psychedelics alter perception). It is non-selective, also acting at serotonin 1A, 2B, and 2C receptors and at dopamine receptors. At 5–20 µg only a fraction of 5-HT2A receptors is engaged, producing subtle shifts in arousal and mood; the threshold for noticeable effects is about 10 µg (Holze et al., 2021, a study co-authored by the Beckley Foundation, a drug-policy reform charity earning no revenue from trial results).

Proposed longer-term mechanisms:

  • Neuroplasticity: in cell and rodent studies, LSD and related psychedelics grow neuronal branches and synapses via TrkB (the receptor for brain-derived neurotrophic factor, BDNF, a protein that supports neuron growth), mTOR (a cell-growth signaling hub), and 5-HT2A signaling (Ly et al., 2018).
  • Anti-inflammatory signaling: 5-HT2A activation outside the brain suppresses inflammatory signaling in cell studies (Yu et al., 2008).

A competing explanation holds that most reported benefits reflect expectancy, amplified because participants can often detect the drug (Szigeti et al., 2021).

Pharmacology: oral bioavailability is about 80% (Arikci et al., 2025); plasma levels peak at about 1.1 hours; the elimination half-life is about 3 hours. LSD distributes widely and enters the brain readily. The liver converts it largely to inactive 2-oxo-3-hydroxy-LSD via CYP1A2, CYP2C9, CYP2E1, and CYP3A4 (drug-metabolizing liver enzymes); CYP2D6 (a related enzyme) forms nor-LSD (Luethi et al., 2019) yet most affects blood levels (Vizeli et al., 2021).

Historical Context & Evolution

Albert Hofmann synthesized LSD at Sandoz in 1938 while screening ergot-derived compounds (chemicals from a grain fungus) for a circulatory and respiratory stimulant; its psychoactivity was discovered by accident in 1943. From 1947 Sandoz supplied it as Delysid for psychiatric research, and studies on alcoholism, depression, and end-of-life distress followed. Pre-prohibition researchers also tested low doses: a systematic review traced studies back to 1955 reporting effects on pain, time perception, and mood (Polito & Liknaitzky, 2022). Recreational spread led to US Schedule I status (the most restrictive drug-control category) in 1970 and international control in 1971, halting most human research for decades — a regulatory decision, not a scientific verdict on the earlier findings.

Microdosing as a self-directed practice was popularized by psychologist James Fadiman’s 2011 book The Psychedelic Explorer’s Guide, which proposed a small dose every third day, and spread through technology-sector culture from about 2015. Its health-optimization appeal rested on self-reported gains in mood, focus, and creativity.

Placebo-controlled trials began in 2019. They confirmed measurable drug effects at 10–20 µg but have largely not reproduced lasting benefits, including an attention-deficit/hyperactivity disorder (ADHD) trial sponsored by Definium Therapeutics, developer of the LSD product MM120 (Mueller et al., 2025). Researchers still disagree over whether null results mean the effects are expectancy-driven, or that trials used too few doses, too-low doses, or healthy rather than clinical samples (Polito & Liknaitzky, 2024).

Expected Benefits

High 🟩 🟩 🟩

Transient Energy and Vigor Lift on Dosing Days

Several placebo-controlled randomized controlled trials (RCTs) show that 5–26 µg raises self-rated vigor, energy, or arousal for several hours (Bershad et al., 2019; Hutten et al., 2020; de Wit et al., 2022). A six-week home-dosing trial sponsored by the LSD-product developer MindBio found higher energy, happiness, and wellness on dose days only (Murphy et al., 2023). Positive-mood gains appear in some trials but not others, and blinding is imperfect because the drug is detectable.

Magnitude: Effects are small and confined to dosing days: in the 80-person home-dosing trial, dose-day ratings rose but no questionnaire or cognitive task changed between baseline and week 6; the trials report no pooled effect size for this outcome.

Medium 🟩 🟩

Longer Sleep After Dosing Days

In a MindBio-sponsored RCT, 80 healthy men took 10 µg or placebo every third day for six weeks while wearing a commercial sleep tracker (Allen et al., 2024). Across 3,231 nights, the LSD group slept longer on the night after each dose, with no loss of sleep on the dosing night and no change in sleep stages. This is a single trial in men using consumer-grade devices, not laboratory sleep recording.

Magnitude: +24.3 minutes of sleep on post-dose nights versus placebo (95% confidence interval [CI, the range likely to contain the true value] 10.3–38.3 minutes).

Low 🟩

Lasting Mood and Depression Relief ⚠️ Conflicted

A MindBio-sponsored open-label trial (no placebo) in 19 depressed adults reported large score drops (Daldegan-Bueno et al., 2026), but MindBio’s 89-person trial against caffeine found no advantage (MindBio phase 2B results), and a healthy-adult meta-analysis found none (Meshkat et al., 2026). Net: blinded trials do not support lasting mood benefit.

Magnitude: Montgomery–Åsberg Depression Rating Scale (MADRS, a clinician depression score) fell 29.9% with LSD versus 36.4% with active placebo at 8 weeks (p = 0.55, meaning the gap is consistent with chance; MindBio phase 2B results); open-label reduction was 59.5%.

Cognitive Performance and Creativity ⚠️ Conflicted

Performance enhancement is the most common reason people microdose (Hutten et al., 2019), and one lab trial found fewer attention lapses at 5 and 20 µg (Hutten et al., 2020). A 14-study meta-analysis found no enhancement in any domain (Pinhas et al., 2026). Net: no reliable cognitive or creative gain.

Magnitude: No cognitive domain improved across 14 studies (1,614 participants); the only pooled effect was a small decline in cognitive control (Cohen’s d, a standardized effect size, −0.34).

ADHD Symptom Relief ⚠️ Conflicted

Self-reports describe better focus in adults with ADHD, but the only RCT — 20 µg twice weekly for six weeks in 53 adults — found no advantage over placebo (Mueller et al., 2025). Net: the controlled evidence shows no benefit beyond placebo.

Magnitude: Adult Investigator Symptom Rating Scale (AISRS, an ADHD severity score) improved −7.1 points with LSD versus −8.9 with placebo (no significant difference).

Higher Pain Tolerance ⚠️ Conflicted

A single 20 µg dose increased tolerance of ice-cold water and lowered pain ratings in 24 healthy adults (Ramaekers et al., 2021). Four 15 µg doses showed no effect (Cavarra et al., 2025). Net: any effect is dose-dependent and unproven in real pain.

Magnitude: Treatment effect on cold-water pain tolerance of partial η² = 0.09 (the share of score variation explained by treatment), driven by the single 20 µg dose; 5, 10, and repeated 15 µg doses showed no effect, and no trial measured clinical pain (Ramaekers et al., 2021).

Speculative 🟨

Neuroplasticity and Brain Resilience

LSD grows neuronal connections in cell and rodent studies (Ly et al., 2018), and low doses acutely raise blood BDNF in humans (Hutten et al., 2021). No human study links this to clinical outcomes.

Anti-Inflammatory and Neurodegeneration Protection

5-HT2A activation blocks tumor necrosis factor (TNF, an inflammatory signal) at tiny concentrations in cell studies (Yu et al., 2008), motivating Alzheimer’s-directed LSD trials. The basis is mechanistic only.

Lifespan Extension

Psilocybin extended survival in aged mice (Kato et al., 2025), and LSD extended roundworm lifespan in an unreviewed preprint (Carrilho et al., 2025). No human lifespan data exist; the basis is animal data only.

Benefit-Modifying Factors

  • CYP2D6 genotype: people with no functional CYP2D6 (“poor metabolizers,” about 5–10% of people of European ancestry) have roughly 75% higher LSD exposure and longer effects, so a given microdose acts like a larger dose (Vizeli et al., 2021).
  • Baseline mood: adults with mildly depressed mood felt stronger positive effects from 26 µg and a larger 48-hour drop in depression scores than non-depressed adults (Molla et al., 2024).
  • Sex: several key trials enrolled men only (sleep, Allen et al., 2024; home-dosing, Murphy et al., 2023); female-specific data are sparse, and a premenstrual-disorder trial is planned.
  • Pre-existing conditions: clinical populations (depression, ADHD) have not shown benefit over placebo; SSRI (selective serotonin reuptake inhibitor antidepressant) users describe blunted effects in older self-reports (Bonson et al., 1996), but a paroxetine RCT found pleasant effects unchanged (Becker et al., 2025).
  • Age: 5–20 µg was tolerated without cognitive or balance impairment in adults averaging 63 years (Family et al., 2020, a trial sponsored by LSD developer Eleusis); benefit data in older adults are absent.

Potential Risks & Side Effects

High 🟥 🟥 🟥

Anxiety and Psychological Discomfort

Anxiety is the most consistent adverse effect in controlled trials. It led 4 of 40 men to withdraw from the LSD arm of a six-week home-dosing RCT (Murphy et al., 2023), appeared at 5 and 20 µg in a laboratory trial (Hutten et al., 2020), and caused one withdrawal in a depression trial (Daldegan-Bueno et al., 2026). It is dose-dependent, acute, and resolves within hours.

Magnitude: 10% (4/40) withdrawal for anxiety on 10 µg versus none on placebo.

Blood Pressure Increase

Doses of 10–20 µg raise systolic and diastolic blood pressure for several hours, usually within the normal range, in single-dose and repeated-dose RCTs (Ramaekers et al., 2021; Cavarra et al., 2025). A systematic review lists it among the most common effects (Modzelewski et al., 2025). Relevance grows with hypertension or cardiovascular disease.

Magnitude: In the 89-person depression trial, blood-pressure or cardiovascular adverse events occurred in 27% on LSD versus 25% on active placebo (MindBio phase 2B results).

Reduced Cognitive Control

Pooled trial data show a small decline in cognitive control — the ability to suppress automatic responses and stay on task — during microdosing (Pinhas et al., 2026). Confusion rose at 20 µg in a laboratory trial (Hutten et al., 2020). The finding pools LSD and psilocybin, with no difference between them.

Magnitude: Cohen’s d −0.34 (95% CI −0.62 to −0.06) across 14 studies, as summarized in an umbrella review by Özaydın & Canlan Özaydın, 2026.

Perceptual and Dissociative Effects

At 10–20 µg, placebo-controlled trials recorded noticeable altered-state effects: feeling “under the influence,” subtle changes in perception, and dissociation (a sense of detachment from surroundings or self) (Hutten et al., 2020; Ramaekers et al., 2021; Holze et al., 2021). The 20 µg dose also raised “bad drug effect” ratings. Effects are acute, rated mild, and end within about 5 hours, but they defeat the aim of staying below the perceptual threshold.

Magnitude: Total dissociation scores rose at 10 and 20 µg versus placebo (partial η² = 0.21), with mean severity ranging from not present to mild (Ramaekers et al., 2021).

Medium 🟥 🟥

Digestive Upset and Headache

Abdominal discomfort, digestive issues, and headache are the most frequently reported physical complaints on dosing days; surveys describe “physiological discomfort” as a common challenge (Modzelewski et al., 2025). In the single large RCT, headache rates matched placebo while digestive complaints ran slightly higher.

Magnitude: Digestive complaints 29% on LSD versus 22% on caffeine placebo; headache 20% versus 22% (MindBio phase 2B results).

Low 🟥

Accidental Overdose from Unmeasured Supply

Illicit blotters and liquids have unknown content, so an intended microdose can become a full psychedelic dose. Most of 1,116 surveyed microdosers did not know their dose (Hutten et al., 2019). Some products sold as LSD contain NBOMe compounds (potent, more toxic synthetic psychedelics) (Zawilska et al., 2020).

Magnitude: Direction only: the majority of surveyed microdosers were unaware of their dose; the literature reports no frequency of accidental full-dose episodes.

Psychosis or Mania in Vulnerable People

Full-dose trials recorded serious psychiatric events, including psychosis, in about 4% of participants with pre-existing psychiatric disorders and none in healthy volunteers (Hinkle et al., 2024). Microdose-specific data are absent.

Magnitude: About 4% serious adverse events at full doses in psychiatric samples; no microdose-specific rate reported.

Persistent Visual Disturbances

Hallucinogen persisting perception disorder (HPPD, lasting visual changes such as trails or halos) is described after repeated LSD use (Halpern & Pope, 2003). No microdosing trial has reported a case.

Magnitude: Not quantified in available studies. Evidence consists of case reports and surveys, and no controlled microdosing study has recorded an occurrence.

Speculative 🟨

Heart-Valve Damage

Chronic serotonin 2B activation caused valve disease with fenfluramine-type appetite suppressants; LSD activates it (Tagen et al., 2023, co-authored by developer Delos Therapeutics). Heart-ultrasound monitoring found no change (Daldegan-Bueno et al., 2026). Evidence is mechanistic.

Risk-Modifying Factors

  • CYP2D6 poor metabolizers: about 75% higher LSD exposure and longer effects raise the odds of anxiety, blood-pressure rise, and unintended perceptual effects at a standard microdose (Vizeli et al., 2021).
  • Baseline blood pressure: trials excluded blood pressure above 140/90 mmHg; pre-existing hypertension amplifies the relevance of dose-related pressure increases.
  • Sex: safety data come from mixed-sex samples, including a 60%-female depression trial (MindBio phase 2B results), but sex-specific safety comparisons are sparse; risks around pregnancy, lactation, and the menstrual cycle are unstudied.
  • Pre-existing conditions: personal or family psychosis, bipolar disorder, panic disorder, heart-valve disease, or seizure disorders raise the risk of serious adverse events.
  • Age: older adults (55–75) tolerated 5–20 µg (Family et al., 2020), but rising valve-disease and hypertension prevalence with age magnifies long-term cardiac uncertainty.

Key Interactions & Contraindications

  • Lithium: absolute contraindication; online reports link psychedelics taken with lithium to seizures in 47% of 62 cases (Nayak et al., 2021).
  • SSRIs (sertraline, fluoxetine, paroxetine, escitalopram): caution; retrospective self-reports describe blunted effects (Bonson et al., 1996), but in an RCT paroxetine left pleasant effects unchanged, possibly because it raises LSD exposure 1.5-fold via CYP2D6 inhibition (Becker et al., 2025); avoiding compensatory dose escalation limits risk.
  • Tricyclic antidepressants (older antidepressants; amitriptyline, nortriptyline) and monoamine oxidase inhibitors (MAOIs, antidepressants that block serotonin breakdown; phenelzine, tranylcypromine): caution; older reports describe altered, sometimes intensified LSD responses (Bonson & Murphy, 1996); serotonergic (serotonin-boosting) load increases; avoiding co-use limits this.
  • Strong CYP2D6 inhibitors (bupropion, fluoxetine, quinidine, terbinafine): monitor; higher LSD levels and longer effects; starting at the lowest dose limits this.
  • Antipsychotics (risperidone, quetiapine, olanzapine): 5-HT2A blockade largely cancels LSD’s effects; monitor, since effects may be absent.
  • Ergot-derived (fungus-derived drugs for Parkinson’s disease, prolactin excess, or migraine) and 5-HT2B (serotonin 2B receptor)-active drugs (cabergoline, pergolide, methysergide): caution; additive heart-valve risk; echocardiographic (heart ultrasound) monitoring detects valve changes.
  • Stimulants (amphetamine, methylphenidate): monitor; additive blood-pressure and anxiety effects; blood-pressure checks on dosing days detect rises.
  • Tramadol: caution; lowers the seizure threshold, adds serotonergic load, and competes for CYP2D6; separate dosing days limit the overlap.
  • Over-the-counter dextromethorphan and pseudoephedrine: caution; dextromethorphan adds serotonergic load and competes for CYP2D6 clearance; pseudoephedrine adds blood-pressure elevation; avoiding these products on dosing days limits the overlap.
  • Supplements with serotonergic action (St. John’s wort, 5-HTP [5-hydroxytryptophan, a serotonin building block], SAMe [S-adenosylmethionine, a mood supplement]): caution; additive serotonergic effects; St. John’s wort also induces CYP3A4, possibly shortening LSD exposure; pausing these supplements during a course avoids this.
  • Supplements with additive stimulant or pressure effects (caffeine, yohimbine, high-dose green tea extract): monitor; additive rises in blood pressure and anxiety; less caffeine on dosing days reduces this.
  • Other psychedelics and “stacks” (psilocybin, cannabis): caution; cannabis can intensify anxiety and perceptual effects; combined psychedelics add 5-HT2A and 5-HT2B load; using one substance at a time avoids stacking.
  • Alcohol: monitor; blunts judgment and complicates recognition of adverse reactions. Separating alcohol from dosing days limits this.

Populations who should avoid Microdosing LSD:

  • Personal history of psychotic disorder, bipolar disorder, or psychotic depression, or a first-degree relative with psychosis
  • People taking lithium
  • Pregnant or breastfeeding women, or those planning pregnancy
  • Known valvular heart disease (more than mild regurgitation or stenosis — leaky or narrowed valves — on echocardiography) or pulmonary hypertension (high pressure in the lung arteries)
  • Uncontrolled hypertension (above 140/90 mmHg) or heart attack or stroke within the past 6 months
  • Epilepsy or prior unprovoked seizure
  • Suicidal ideation or attempt within the past 12 months
  • History of hallucinogen persisting perception disorder
  • Active substance use disorder (within the past 12 months)
  • Adolescents and adults under 21, whose brains are still developing
  • People subject to drug testing or legal penalties, where possession is prohibited

Risk Mitigation Strategies

  • Lowest effective dose: trials start at 5–10 µg, the threshold for noticeable effects; titrating up by 2–5 µg only if needed reduces anxiety, blood-pressure rise, and cognitive-control impairment.
  • Spacing doses every 3–4 days: twice-weekly schedules showed no tolerance in trials, limiting cumulative serotonin 2B receptor exposure implicated in heart-valve risk.
  • Time-limited courses: trial courses lasted 4–8 weeks; capping courses at 8 weeks with breaks limits unknown long-term valve and psychiatric risks.
  • Volumetric dosing: dissolving a known quantity in a measured volume of distilled water or ethanol, then measuring doses by syringe, reduces the risk of accidental full doses from uneven blotters.
  • Reagent testing: an Ehrlich reagent test turns purple with LSD but not with NBOMe compounds, reducing the risk of toxic substitution; formal drug-checking services give fuller analysis.
  • Screening before starting: a psychiatric and family history screen for psychosis or bipolar disorder, a medication review for lithium and CYP2D6 inhibitors, and a baseline blood pressure reduce serious-event risk.
  • Blood-pressure checks on dosing days: measuring 1–3 hours after a dose detects clinically relevant rises; readings above 140/90 mmHg signal stopping.
  • Baseline and periodic echocardiography: for courses beyond 3 months, an echocardiogram at baseline and every 6–12 months detects early valve changes.
  • No driving or safety-critical work: avoiding driving for 6 hours after dosing mitigates the risk from reduced cognitive control and unexpected perceptual effects.
  • Morning dosing: taking doses early in the day places the roughly 5-hour acute window of anxiety, blood-pressure rise, and reduced cognitive control in daytime hours, when post-dose blood-pressure checks are feasible and driving can be scheduled around it.

Therapeutic Protocol

  • Fadiman protocol: popularized by psychologist James Fadiman — one dose of about 10 µg, then two days off (dose every third day), for 4–10 weeks, followed by a break of 2–4 weeks.
  • Clinical-trial home regimen: 10 µg every third day for six weeks (14 doses), first dose supervised (Murphy et al., 2023).
  • Titrated twice-weekly regimen: 8 µg first dose, then 6–20 µg twice weekly for eight weeks, adjusted to a barely noticeable effect (Daldegan-Bueno et al., 2026).
  • Fixed higher microdose: 20 µg twice weekly for six weeks, used in the adult ADHD trial (Mueller et al., 2025).
  • Luteal-phase dosing: 10 µg daily or every other day during the premenstrual phase, an approach drawn from anecdotal reports and now under trial for premenstrual disorders at University Hospital Basel (NCT07189299).
  • Time of day: morning dosing is typical; effects of 10 µg begin at about 1 hour, peak at 2.5 hours, and end by about 5 hours (Holze et al., 2021).
  • Half-life: plasma elimination half-life is about 2.7–3 hours; effects outlast plasma levels because LSD binds slowly releasing receptor sites.
  • Single dose: each microdose is taken once, not split, since the effect profile depends on peak concentration.
  • Genetic polymorphisms: CYP2D6 poor metabolizers reach about 75% higher exposure; practitioners start at the low end (5 µg) when genotype is known or effects feel unexpectedly strong.
  • Sex: no sex-based dosing differences are established; trials used the same doses in men and women, and cycle-linked dosing is under study.
  • Age: 5–20 µg every fourth day was tolerated in adults aged 55–75 (Family et al., 2020); older adults typically start at 5 µg given higher cardiovascular risk.
  • Baseline biomarkers: baseline blood pressure and mood scores guide eligibility; depressed mood predicts stronger acute effects at the same dose.
  • Pre-existing conditions: with CYP2D6-inhibiting SSRIs such as paroxetine, no LSD dose change appears necessary (Becker et al., 2025); lithium users and people with psychotic or bipolar disorders are excluded from protocols.
  • Intention-setting variant: pairing each dose with a chosen activity (exercise, creative work, time outdoors), used in the depression trials and described by researchers of “set and setting” (Hartogsohn & Petranker, 2022).

Discontinuation & Cycling

  • Short-term by design: microdosing is used in defined courses of 4–10 weeks, not lifelong; no data support indefinite continuous use.
  • Withdrawal effects: no withdrawal syndrome has been documented; LSD has low dependence potential, and trial participants stopped abruptly without reported rebound symptoms.
  • Tapering: not required; courses can be stopped at any dose. Abruptly stopping a co-prescribed antidepressant carries its own withdrawal risk, independent of LSD.
  • Tolerance: daily LSD produces rapid tolerance as target receptors become less responsive; dosing every 3–4 days avoids measurable tolerance (Daldegan-Bueno et al., 2026).
  • Cycling: community protocols use 4–8 weeks on followed by 2–4 weeks off to reassess effects and limit cumulative serotonin 2B receptor exposure; no trial has tested cycling itself.

Sourcing and Quality

  • Legal status: LSD is a controlled substance in nearly all countries; outside clinical trials there is no legal, quality-controlled source, and pharmaceutical products (MM120, MB22001) are investigational only.
  • Unknown potency: illicit blotters vary widely in content and degrade with light, heat, and humidity; label claims are unreliable, making the actual dose uncertain.
  • Adulteration: NBOMe compounds and other synthetic psychedelics are sold as LSD and carry seizure and fatality risks at tiny doses; a bitter or numbing blotter suggests substitution.
  • Testing: Ehrlich reagent kits turn purple with LSD and related compounds, confirming an LSD-type substance; anonymous drug-checking services (e.g., Energy Control, DrugsData) provide laboratory confirmation. No reputable legal brands or compounding pharmacies exist.
  • Salt form: LSD base and LSD tartrate formulations are bioequivalent in absorption (Arikci et al., 2025), but label doses may refer to either form.
  • LSD analogs: 1P-LSD and similar “research chemicals” act as prodrugs converted almost fully to LSD in humans (Grumann et al., 2020); their legal status varies and purity is unverified.
  • Storage: LSD solutions are kept in dark glass, refrigerated, away from chlorinated tap water, which degrades LSD.

Practical Considerations

  • Time to effect: acute effects start about 1 hour after a dose; trials found no cumulative benefit emerging over 6–8 weeks, so any effect is typically noticed on dosing days.
  • Common pitfalls: unknown dose from illicit supply; escalating doses to feel something; dosing too often, causing tolerance; attributing expectancy effects to the drug; and combining with lithium, stimulants, or other psychedelics.
  • Regulatory status: LSD is Schedule I in the United States and controlled under the 1971 United Nations convention; no regulator has approved it for any indication; psilocybin-access programs (Oregon, Colorado, Australia) exclude LSD.
  • Cost and accessibility: illicit LSD is inexpensive but carries criminal, employment, and immigration risks; legal access exists only through clinical trials.
  • Structural incentives: generic LSD offers no patent revenue, whereas patented formulations (MM120, MB22001) give developers an incentive to publish favorable results; institutional payers have no current coverage stake in either.
  • Evidence funding: much of the trial evidence is funded by companies developing LSD products (MindBio, Eleusis, and MM120’s developer Definium Therapeutics) or by the Beckley Foundation, a drug-policy reform charity without direct revenue from trial results.

Interaction with Foundational Habits

  • Sleep: direct, mildly potentiating; a 10 µg microdose added about 24 minutes of sleep on the following night without disrupting the dosing night in healthy men (Allen et al., 2024). Morning dosing avoids stimulation near bedtime; tracking sleep with a wearable shows individual response.
  • Nutrition: none known pharmacologically; no food interaction is documented. In a 365-person survey, microdosers reported less drinking and dietary changes, especially when starting with a stated intention (Prochazkova et al., 2026). No nutrient depletion is documented.
  • Exercise: indirect; surveyed microdosers reported more walking and activity (Prochazkova et al., 2026), possibly via increased energy on dosing days. Transient blood-pressure elevation argues for moderate rather than maximal-effort sessions in the first 3 hours after a dose.
  • Stress management: indirect, both potentiating and blunting; surveyed microdosers reported more meditation and stress management (Prochazkova et al., 2026), but anxiety is the most common adverse effect. Pairing doses with calm, familiar settings and contemplative practice is common; high-stress days tend to amplify anxiety.

Monitoring Protocol & Defining Success

Baseline testing before a microdosing course establishes cardiovascular and psychiatric eligibility and a personal reference point. It includes a resting blood pressure and heart rate, a psychiatric and family-history screen, validated mood and anxiety questionnaires, one to two weeks of wearable sleep data, and a medication review. For planned courses longer than three months, a baseline echocardiogram documents valve status; CYP2D6 genotyping identifies people likely to have higher exposure.

Ongoing monitoring follows a set cadence: blood pressure 1–3 hours after the first dose and then weekly on dosing days; mood and anxiety questionnaires at 2, 4, and 8 weeks and at course end; sleep data continuously; and, for use beyond three months, an echocardiogram every 6–12 months. Success is defined as a sustained, self-tracked improvement beyond the pre-course baseline without new adverse effects.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
Blood pressure <120/80 mmHg Microdoses raise pressure Conventional target <130/80 mmHg; seated, rested; measure 1–3 hours post-dose
Resting heart rate 50–70 bpm Cardiovascular load Conventional range 60–100 bpm; morning measurement before caffeine
Echocardiogram (heart valves) No more than trace regurgitation Valve-risk surveillance No established microdosing guideline; pair with a stethoscope check for new murmurs
NT-proBNP <125 pg/mL Heart-strain screen N-terminal pro-B-type natriuretic peptide, a blood marker of heart strain; conventional cut-offs rise with age; pair with echocardiogram
PHQ-9 score 0–4 Tracks depressive symptoms Patient Health Questionnaire-9, a 9-item depression scale; conventional “minimal” range is also 0–4; same time of day each assessment
GAD-7 score 0–4 Tracks anxiety Generalized Anxiety Disorder-7, a 7-item anxiety scale; anxiety is the leading adverse effect
Sleep duration (wearable) 7–9 hours; no fixed target for change — track against own baseline Documented sleep effect Compare post-dose nights with non-dose nights; consumer devices misclassify sleep stages
CYP2D6 genotype Normal metabolizer Predicts LSD exposure One-time test; poor metabolizers have about 75% higher exposure
Cognitive control (Stroop or similar app task) No established target — track change from own baseline Detects cognitive-control decline Stroop: a color-word interference test; test on dosing and non-dosing days at the same time of day

Qualitative markers:

  • Mood stability and absence of dose-day anxiety
  • Energy and motivation on dosing versus non-dosing days
  • Subjective sleep quality and morning alertness
  • Focus and work quality, rated before unblinding if self-blinding
  • Absence of visual disturbances between doses
  • Social connectedness and irritability

Emerging Research

  • Premenstrual disorders (L4Her): a randomized, placebo-controlled trial of 10 µg LSD daily or every other day during the premenstrual phase for three cycles in 150 women with premenstrual syndrome or premenstrual dysphoric disorder (a severe, mood-dominated form of premenstrual syndrome) (NCT07189299); not yet recruiting, estimated primary completion 2029.
  • Depression mechanism trial (MESA-D): a completed crossover trial (each participant receives both treatments) of a single 26 µg dose versus placebo in 41 adults with major depressive disorder, measuring 48-hour mood, reward processing, and sleep EEG (electroencephalography, brain-wave recording) (NCT07017478); results pending.
  • Expectancy trial (MESA-X): a completed four-arm trial in 42 healthy adults giving 13 µg or placebo with the substance either disclosed or uncertain, separating drug from expectation (NCT07061886); results could strengthen or weaken microdosing claims.
  • Placebo-controlled depression trial (LSDDEP2): MindBio’s 89-person trial versus active placebo found no advantage at 8 weeks (registered in Australia/New Zealand as ACTRN12624000128594, no NCT ID; protocol: Daldegan-Bueno et al., 2024; MindBio phase 2B results); peer-reviewed publication will allow independent scrutiny, following the positive open-label phase (Daldegan-Bueno et al., 2026).
  • Heart-valve safety: chronic serotonin 2B activation is the leading long-term concern (Tagen et al., 2023, authored partly by staff of Delos Therapeutics, a psychedelic-drug developer); longer echocardiographic follow-up could confirm or dismiss it.
  • Aging and neurodegeneration: tolerability in older adults (Family et al., 2020) and psilocybin’s survival gain in aged mice (Kato et al., 2025) motivate longevity-focused trials, none yet registered for LSD.
  • Individual response variability: brain-response differences to low doses (Hutten et al., 2024) and CYP2D6 genotype could explain mixed trial results and support personalized dosing.

Conclusion

Microdosing LSD means taking a small amount of the psychedelic drug every few days, below the level that changes perception. For health-focused adults, the evidence now separates what the drug reliably does from what users hope it does. On dosing days it produces a small, short-lived lift in energy, and one well-run study found somewhat longer sleep on the following night. The larger promises — lasting better mood, relief of depression or attention problems, sharper thinking, more creativity — have not held up when people did not know whether they were taking the drug or a placebo. Studies of pain relief disagree, and ideas about brain repair, inflammation, and longer life rest on laboratory and animal work only.

The risks are usually mild and brief: anxiety, a modest rise in blood pressure, digestive upset, and slightly weaker self-control over attention on dosing days. Less certain but more serious are rare psychiatric reactions in vulnerable people, accidental full doses from unregulated supply, and a theoretical long-term threat to heart valves that no study has yet ruled in or out. Legal risk is real in most countries.

The evidence base is small, short, and mostly in healthy younger adults, and much of it is funded by companies developing patented LSD products or by a charity campaigning for drug-policy reform that earns no money from the results. For this audience, the balance on current evidence is modest short-term effects set against real uncertainty over long-term safety.

Top - Benefits - Risks - Protocol